Alginate/Chitosan Particle-Based Drug Delivery Systems for Pulmonary Applications

Hill, Marcus; Twigg, Matthew; Sheridan, Emer A.; Hardy, John G.; Elborn, J. Stuart; Taggart, Clifford C.; Scott, Christopher J.; Migaud, Marie E.

doi:10.3390/pharmaceutics11080379

Submit to this Journal Review for this Journal Edit a Special Issue

Article Menu

...

Open AccessCommunication

Alginate/Chitosan Particle-Based Drug Delivery Systems for Pulmonary Applications

¹,

²,

^4,5,*

^6,*,

^2,*,

^7,* and

^1,8,*

School of Pharmacy, Queen’s University Belfast Queen’s University Belfast, Belfast BT7 1NN, UK

Airway Innate Immunity Group (AiiR), Wellcome Wolfson Institute of Experimental Medicine, School of Medicine, Dentistry and Biomedical Sciences, Queen’s University Belfast, 97 Lisburn Road, Belfast BT9 7BL, Northern Ireland, UK

Lancashire Teaching Hospitals NHS Foundation Trust, Royal Preston Hospital, Sharoe Green Lane PR2 9HT, UK

⁴

Department of Chemistry, Lancaster University, Lancaster, Lancashire LA1 4YB, UK

⁵

Materials Science Institute, Lancaster University, Lancaster, Lancashire LA1 4YB, UK

⁶

School of Medicine, Dentistry and Biomedical Sciences, Queen’s University Belfast, 97 Lisburn Road, Belfast BT9 7BL, Northern Ireland, UK

⁷

Centre for Cancer Research and Cell Biology, School of Medicine, Dentistry and Biomedical Sciences, Queen’s University Belfast, 97 Lisburn Road, Belfast BT9 7BL, Northern Ireland, UK

⁸

USA Mitchell Cancer Institute, University of South Alabama, Mobile, AL 36604, USA

Authors to whom correspondence should be addressed.

Pharmaceutics 2019, 11(8), 379; https://doi.org/10.3390/pharmaceutics11080379

Received: 30 June 2019 / Revised: 19 July 2019 / Accepted: 24 July 2019 / Published: 2 August 2019

(This article belongs to the Special Issue Mucoadhesive and Mucosal Drug Delivery Systems)

View Full-Text Download PDF

Browse Figures

Citation Export

Abstract

Cystic fibrosis (CF) is a complex, potentially life-threatening disease that is most effectively treated through the administration of antibiotics (e.g., colistimethate sodium). Chronic infection with Pseudomonas aeruginosa is one of the most significant events in the pathogenesis of cystic fibrosis, and tobramycin is the treatment of choice for those patients with chronic P. aeruginosa infection who are deteriorating despite regular administration of colistimethate sodium. Effective treatment can be challenging due to the accumulation of thickened mucus in the pulmonary environment, and here we describe the results of our investigation into the development of alginate/chitosan particles prepared via precipitation for such environments. Tobramycin loading and release from the alginate/chitosan particles was investigated, with evidence of both uptake and release of sufficient tobramycin to inhibit P. aeruginosa in vitro. Functionalisation of the alginate/chitosan particles with secretory leukocyte protease inhibitor (SLPI) was shown to help inhibit the inflammatory response associated with lung infections (via inhibition of neutrophil elastase activity) and enhance their interaction with cystic fibrosis mucus (assayed via reduction of the depth of particle penetration into the mucus) in vitro, which have prospects to enhance their efficacy in vivo. View Full-Text

Keywords: biomedical applications; drug delivery systems; particles; antimicrobial

▼ Show Figures

Graphical abstract

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited

Supplementary Material

Supplementary File 1:
PDF-Document (PDF, 2654 KiB)

Share and Cite

MDPI and ACS Style

Hill, M.; Twigg, M.; Sheridan, E.A.; Hardy, J.G.; Elborn, J.S.; Taggart, C.C.; Scott, C.J.; Migaud, M.E. Alginate/Chitosan Particle-Based Drug Delivery Systems for Pulmonary Applications. Pharmaceutics 2019, 11, 379. https://doi.org/10.3390/pharmaceutics11080379

AMA Style

Hill M, Twigg M, Sheridan EA, Hardy JG, Elborn JS, Taggart CC, Scott CJ, Migaud ME. Alginate/Chitosan Particle-Based Drug Delivery Systems for Pulmonary Applications. Pharmaceutics. 2019; 11(8):379. https://doi.org/10.3390/pharmaceutics11080379

Chicago/Turabian Style

Hill, Marcus, Matthew Twigg, Emer A. Sheridan, John G. Hardy, J. S. Elborn, Clifford C. Taggart, Christopher J. Scott, and Marie E. Migaud. 2019. "Alginate/Chitosan Particle-Based Drug Delivery Systems for Pulmonary Applications" Pharmaceutics 11, no. 8: 379. https://doi.org/10.3390/pharmaceutics11080379

Find Other Styles

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Metrics

Abstract views Pdf views Html views

Article Menu

Alginate/Chitosan Particle-Based Drug Delivery Systems for Pulmonary Applications

Abstract

Supplementary Material

Share and Cite

Article Metrics

Article Access Statistics

Article Access Map by Country/Region

Further Information

Guidelines

MDPI Initiatives

Follow MDPI